Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Valproate for the Treatment of Residual Amblyopia

NCT07226141 is registered in ClinicalTrials.gov with Boston Children's Hospital as lead sponsor.

NCT NCT07226141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07226141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Valproate for the Treatment of Residual Amblyopia
Lead sponsor
Boston Children's Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 1, 2026
Completion date
September 30, 2027
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

amblyopia, amblyopia strabismic, amblyopia unilateral, amblyopia, anisometropic